{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=brimonidine+0.1%25",
    "query": {
      "intervention": "brimonidine 0.1%"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-21T10:15:12.785Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00697541",
      "title": "Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Erythematous Rosacea"
      ],
      "interventions": [
        {
          "name": "0.18% COL-118 facial gel (1.8 mg brimonidine)",
          "type": "DRUG"
        },
        {
          "name": "0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)",
          "type": "DRUG"
        },
        {
          "name": "Advanced Eye Relief",
          "type": "DRUG"
        },
        {
          "name": "COL-118 facial gel vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2008-05",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2021-02-18",
      "last_synced_at": "2026-09-21T10:15:12.785Z",
      "location_count": 1,
      "location_summary": "Broomall, Pennsylvania",
      "locations": [
        {
          "city": "Broomall",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00697541"
    },
    {
      "nct_id": "NCT00698945",
      "title": "Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open-Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "Istalol and Optive",
          "type": "DRUG"
        },
        {
          "name": "Alphagan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bp Consulting, Inc",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2008-06",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2008-12-04",
      "last_synced_at": "2026-09-21T10:15:12.785Z",
      "location_count": 1,
      "location_summary": "Petaluma, California",
      "locations": [
        {
          "city": "Petaluma",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00698945"
    },
    {
      "nct_id": "NCT00440141",
      "title": "Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "latanoprost 0.005% eye drops and brimonidine 0.1% eye drops",
          "type": "DRUG"
        },
        {
          "name": "latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2006-07",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2008-01-02",
      "last_synced_at": "2026-09-21T10:15:12.785Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00440141"
    },
    {
      "nct_id": "NCT06449352",
      "title": "Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Normal Tension Glaucoma"
      ],
      "interventions": [
        {
          "name": "Netarsudil",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Westlake Eye Specialists",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-06-13",
      "completion_date": "2025-09-22",
      "has_results": false,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-09-21T10:15:12.785Z",
      "location_count": 4,
      "location_summary": "Austin, Texas • Killeen, Texas • Kyle, Texas + 1 more",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Killeen",
          "state": "Texas"
        },
        {
          "city": "Kyle",
          "state": "Texas"
        },
        {
          "city": "New Braunfels",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06449352"
    },
    {
      "nct_id": "NCT00457795",
      "title": "24-hour IOP-lowering Effect of Brimonidine 0.1%",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Open-angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "brimonidine 0.1% (Alphagan® P)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 15,
      "start_date": "2006-12",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2011-11-24",
      "last_synced_at": "2026-09-21T10:15:12.785Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00457795"
    },
    {
      "nct_id": "NCT00567411",
      "title": "Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "brimonidine 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Apraclonidine 0.5%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Walter Reed Army Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2006-08",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2007-12-05",
      "last_synced_at": "2026-09-21T10:15:12.785Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00567411"
    },
    {
      "nct_id": "NCT04007276",
      "title": "The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Glaucoma, Open-Angle",
        "Glaucoma; Drugs",
        "Droopy Eyelid",
        "Ptosis",
        "Glaucoma, Primary Open Angle"
      ],
      "interventions": [
        {
          "name": "brimonidine tartrate ophthalmic solution 0.025%",
          "type": "DRUG"
        },
        {
          "name": "sterile balanced saline solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Tulane University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-11-10",
      "completion_date": "2036-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-09-21T10:15:12.785Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04007276"
    },
    {
      "nct_id": "NCT01525173",
      "title": "A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "0.1% brimonidine tartrate ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "0.01% bimatoprost ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "0.2% hypromellose lubricant eye drops",
          "type": "DRUG"
        },
        {
          "name": "latanoprost 0.005% ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 137,
      "start_date": "2012-01",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-09-21T10:15:12.785Z",
      "location_count": 1,
      "location_summary": "Deerfield Beach, Florida",
      "locations": [
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01525173"
    },
    {
      "nct_id": "NCT01345448",
      "title": "Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Brimonidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo Lotion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nanduri, Padma, M.D., FACS",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2011-04",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2011-05-02",
      "last_synced_at": "2026-09-21T10:15:12.785Z",
      "location_count": 1,
      "location_summary": "Visalia, California",
      "locations": [
        {
          "city": "Visalia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01345448"
    },
    {
      "nct_id": "NCT00652483",
      "title": "Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Brimonidine ophthalmic solution 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Brimonidine ophthalmic solution 0.2%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 433,
      "start_date": "2003-05",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2008-04-03",
      "last_synced_at": "2026-09-21T10:15:12.785Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00652483"
    }
  ]
}